---
title: "alki in nsclc"
slug: "alki-in-nsclc"
date: "2023-12-12"
enableToc: false
tags:
  - building
---

> [!info]
>
> 🌱 來自: [[ALK]]

# alki in nsclc

<!-- _paginate: false -->

#### KFSYSCC Fellowship Tuesday Morning Journal Club

### 2023-12-12

# <!--fit-->**Treatment of <br>ALK Translocation-Positive<br>Non-Small Cell Lung Cancer**

<br>

#### (1)Presenter, 專研醫師, 和信治癌中心醫院腫瘤內科部

#### (2)Moderator, 主治醫師, 和信治癌中心醫院腫瘤內科部

---

<!-- _header: 'Outline' -->

# Outline

- Clinical Scenario
- Introduction to ALK mutation
- Current ALK treatment landscape
  - Crizotinib
  - Alectinib
  - Brigatinib
  - Lorlatiib
    - Lorlatiib toxicity
- ALKi resistance
- Take home messages

---

<!-- header: 'Clinical Scenario' -->

# <!--fit-->Clinical<br>Scenario

---

## Patient 1 58-year-old man

:::free

- Lung cancer, RML,
- Adenocarcinoma,
- acinar predominant with pleural mets,
- s/p wedge resection on 2017/09/26 (義大)
- pT4NXM1a
- EGFR mutation(-), ALK(+)

:::split

#### Treatment course

- crizotinib
  - PD in 6 month
- pemetrexed / carboplatin
- alectinib 2018~Now
  - SD

:::

> ID: 05682406

---

### Patient 2: 49-year-old man

- Lung cancer, Adenocarcinoma, RLL, cT3N3M1c with lung-lung and brain metastases and pleural seedings, EGFR(-), ALK(+), ROS1(-), s/p alectinib, stable disease

:::free

![Figure: height:450px](https://i.imgur.com/hUHXE15.png)

:::split

![Figure: height:450px](https://i.imgur.com/FDz4Zgg.png)

:::

---

## Increasing number of FDA-approved drugs for treatment of oncogene-addicted NSCLC

![Figure: height:450px](https://i.imgur.com/bjf7aqp.png)

> Delahaye C, Figarol S, Pradines A, Favre G, Mazieres J, Calvayrac O. Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. Cancers. 2022;14(11):2613. doi:10.3390/cancers14112613

---

<!-- header: '' -->

# What is ALK?

## Anaplastic lymphoma kinase and ALK inhibitors

![Figure: height:200px](https://i.imgur.com/nrP62XI.jpg)

![bg right:50% ](https://i.imgur.com/dq1dM4L.png)

> Huang H. Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. International Journal of Molecular Sciences. 2018;19(11):3448. doi:10.3390/ijms19113448

---

## Domain structure of receptor tyrosine kinase families

![Figure: height:480px](https://i.imgur.com/Qzoz3bH.png)

> Hallberg B, Palmer RH. Crizotinib - Latest Champion in the Cancer Wars? New England Journal of Medicine. 2010;363(18):1760-1762. doi:10.1056/NEJMe1010404

---

## Gene fusion between EML4 and ALK

![Figure: height:200px](https://i.imgur.com/Bry6l67.png)

![Figure: height:150px](https://i.imgur.com/4thHEcD.jpg)

![bg fit right:60% height:550px](https://i.imgur.com/7CemBB4.png)

> Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561-566. doi:10.1038/nature05945

---

## Signaling Pathways Activated by ALK Fusion Proteins

:::free

![Figure: height:450px](https://i.imgur.com/wQozSLA.png)

:::split

![Figure: height:450px](https://i.imgur.com/zOyJejT.png)

:::

> Hallberg B, Palmer RH. Crizotinib - Latest Champion in the Cancer Wars? New England Journal of Medicine. 2010;363(18):1760-1762. doi:10.1056/NEJMe1010404

---

![Figure: height:600px](https://i.imgur.com/HS0mcYG.png)

> Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. Nat Cancer. 2023;4(3):330-343. doi:10.1038/s43018-023-00515-0

---

## Therapeutic Sequencing in ALK NSCLC

![Figure: height:500px](https://i.imgur.com/Y2q1xES.png)

> Elsayed M, Christopoulos P. Therapeutic Sequencing in ALK+ NSCLC. Pharmaceuticals. 2021;14(2):80. doi:10.3390/ph14020080

---

<!-- NCCN -->

![bg height:650px](https://i.imgur.com/f26T5XA.png)

---

<!-- NCCN -->

![bg height:550px](https://i.imgur.com/jwV8Ysx.png)

---

<!-- header: 'PROFILE 1014: Crizotinib' -->

# <!--fit-->Crizotinib

## 1st generation ALKi

---

## First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

<br>

:::columns

1. Design:
   - Phase 3 trial, Open-label
   - Multicenter, Randomized
2. 343 patients
3. Patients characteristics:
   - Advanced ALK-positive NSCLC
   - no previous systemic treatment

:::split

4. Agent:
   - crizotinib (250 mg twice daily) in a 3-week cycle
   - pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 weeks.
5. First-line treatment for advanced ALK-positive non-small-cell lung cancer
6. Trial Name: PROFILE 1014

:::

> Solomon BJ, Mok T, Kim DW, et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine. 2014;371(23):2167-2177. doi:10.1056/NEJMoa1408440

---

![Figure: width:850px](https://i.imgur.com/rGdKq62.png)

| Outcome                     | Crizotinib  | Chemotherapy |
| --------------------------- | ----------- | ------------ |
| PFS (median)                | 10.9 months | 7.0 months   |
| Response rate               | 74%         | 45%          |
| HR for progression or death | 0.45        | -            |
| Hazard ratio for death      | 0.82        | -            |

> Solomon BJ, Mok T, Kim DW, et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine. 2014;371(23):2167-2177. doi:10.1056/NEJMoa1408440

---

<!-- header: 'Crizotinib in ROS1' -->

## Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer

:::free

Median progression-free survival was 19.2 months

![Figure: height:450px](https://i.imgur.com/SBxFQVw.png)

:::split

- 50 patients
- Dx by NGS
- phase 1
- ORR: 72%

:::

---

![bg height:450px](https://i.imgur.com/qExyE8k.png)

> 圍毆 - 梗圖產生 ↪ 器 (手工模式) . Accessed November 28, 2023. <https://memes.tw/maker/painter/742>

---

<!-- header: 'ALEX: Alectinib 1L' -->

# <!--fit-->Alectinib

## <!--fit-->2nd generation of ALKi

`ALEX`, `J-ALEX`, `ALESIA`, `ALUR`

---

## Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer

:::free

- Phase 3, Open-label
- Multicenter, Randomized
- 303 patients, 1:1
  - untreated, advanced ALK+ NSCLC
  - including those with asx CNS disease
- Agent:
  - Alectinib 600 mg BID
  - Crizotinib 250 mg BID

:::split

| Outcome                                       | Alectinib   | Crizotinib |
| --------------------------------------------- | ----------- | ---------- |
| Investigator-assessed PFS (median)            | Not reached | -          |
| 12-month event-free survival rate             | 68.4%       | 48.7%      |
| Hazard ratio for disease progression or death | 0.47        | -          |
| Time to CNS progression (cause-specific HR)   | 0.16        | -          |
| Objective response rate                       | 82.9%       | 75.5%      |
| Grade 3 to 5 adverse events                   | 41%         | 50%        |

:::

> Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2017;377(9):829-838. doi:10.1056/NEJMoa1704795

---

![Figure: height:570px](https://i.imgur.com/vkzk83w.png)

> Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2017;377(9):829-838. doi:10.1056/NEJMoa1704795

---

![Figure: width:1180px](https://i.imgur.com/ojZIG8u.png)

> Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2017;377(9):829-838. doi:10.1056/NEJMoa1704795

---

<!-- header: 'J-ALEX: Alectinib in Japan' -->

## Alectinib vs crizotinib in ALK+ NSCLC (J-ALEX): <br>an open-label, randomised phase 3 trial

:::free

- Multi-center trial conducted in Japan
- 103 vs 104 patients
- Chemotherapy-naive or had received one previous chemotherapy regimen
- Agents:
  - alectinib **300 mg** BID
  - crizotinib 250 mg BID
- Primary endpoint: PFS

:::split

| Outcome                                  | Alectinib                 | Crizotinib                    |
| ---------------------------------------- | ------------------------- | ----------------------------- |
| Median PFS                               | Not estimated             | 10.2 months (95% CI 8.2-12.0) |
| Hazard ratio                             | 0.34 (99.7% CI 0.17-0.71) | -                             |
| Grade 3 or 4 adverse events              | 27 (26%) of 103           | 54 (52%) of 104               |
| Dose interruptions due to adverse events | 30 (29%) of 103           | 77 (74%) of 104               |
| DC of study drug due to AEs              | 9 (9%)                    | 21 (20%)                      |

- Alectinib dose (300 mg twice daily) is lower than the approved dose in countries other than Japan

:::

> Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. The Lancet. 2017;390(10089):29-39. doi:10.1016/S0140-6736(17)30565-2

---

#### (A), by line of treatment (B), and by disease stage (C). Hazard ratios were estimated by a stratified Cox analysis

:::free

![Figure: height:500px](https://i.imgur.com/MEYexvf.png)

:::split

![Figure: height:300px](https://i.imgur.com/Dwkdc8u.png)

:::

> Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. The Lancet. 2017;390(10089):29-39. doi:10.1016/S0140-6736(17)30565-2

---

<!-- header: 'ALESIA: Alectinib in Asia' -->

![bg](https://i.imgur.com/vdYs1NN.jpg)

---

## Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA)

:::free

1. Design:

- Phase 3, Randomized
- Open-label,
- Recruiting only Asian: China, South Korea, and Thailand

2. Number of patients: 187
   - Asian patients
   - asymptomatic CNS metastases were permitted

:::split

4. Agent:

- Alectinib (600 mg twice per day)
- Crizotinib (250 mg)

5. Treatment line: First-line treatment for ALK-positive non-small-cell lung cancer

6. Trial Name or NCT Number: NCT02838420

:::

> Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. The Lancet Respiratory Medicine. 2019;7(5):437-446. doi:10.1016/S2213-2600(19)30053-0

---

7. Comparison of two groups:

| Endpoint                                                                   | Alectinib                           | Crizotinib                              |
| -------------------------------------------------------------------------- | ----------------------------------- | --------------------------------------- |
| Investigator-assessed progression-free survival                            | HR 0·22, 95% CI 0·13-0·38, p<0·0001 | Median PFS not estimable vs 11·1 months |
| Independent review committee-assessed progression-free survival            | HR 0·37, 0·22-0·61, p<0·0001        | Not reported                            |
| Objective response                                                         | 91% of 125                          | 77% of 62                               |
| Duration of response                                                       | HR 0·22, 95% CI 0·12-0·40, p<0·0001 | Not reported                            |
| Time to CNS progression                                                    | Cause-specific HR 0·14              | Not reported                            |
| CNS objective response (measurable or non-measurable baseline CNS lesions) | 73% of 44 patients                  | 22% of 23 patients                      |
| Grade 3-5 adverse events                                                   | 29% of 125                          | 48% of 62                               |
| Serious adverse events                                                     | 15% of 125                          | 26% of 62                               |

> Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. The Lancet Respiratory Medicine. 2019;7(5):437-446. doi:10.1016/S2213-2600(19)30053-0

---

## OS

![Figure: height:520px](https://i.imgur.com/dR9gjXt.png)

> Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. The Lancet Respiratory Medicine. 2019;7(5):437-446. doi:10.1016/S2213-2600(19)30053-0

---

![Figure: height:550px](https://i.imgur.com/pvxo77b.png)

> Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. The Lancet Respiratory Medicine. 2019;7(5):437-446. doi:10.1016/S2213-2600(19)30053-0

---

<!-- header: 'ALUR: Alectinib as 2L' -->

## Alectinib versus chemotherapy in crizotinib pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer

:::free

1. Design:

- Trial phase: III, Multi-center
- Randomized, Open-label

2. Number of patients: 107
   - Advanced/metastatic ALK-positive non-small-cell lung cancer patients
   - Previously treated with platinum-based doublet chemotherapy and crizotinib

:::split

4. Agent:

- Alectinib 600 mg twice daily
- or chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, both every 3 weeks)

5. Treatment line: Patients who have progressed on, or were intolerant to, crizotinib

6. Trial Name or NCT Number: `ALUR`, NCT02604342

:::

> Novello S, Mazières J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409-1416. doi:10.1093/annonc/mdy121

---

## Outcome

| Outcome                                        | Alectinib                    | Chemotherapy                |
| ---------------------------------------------- | ---------------------------- | --------------------------- |
| PFS by investigator assessment,                | 9.6 months (95% CI:6.9-12.2) | 1.4 months (95% CI:1.3-1.6) |
| PFS by Independent Review Committee assessment | 7.1 months (95% CI:6.3-10.8) | 1.6 months (95% CI:1.3-4.1) |
| CNS ORR                                        | 54.2%                        | 0%                          |

![Figure: width:950px](https://i.imgur.com/ANYVyYe.png)

> Novello S, Mazières J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409-1416. doi:10.1093/annonc/mdy121

---

<!-- header: 'Brigatinib' -->

# <!--fit-->Brigatinib

## <!--fit-->2nd generation ALKi

`ALTA-1L`, `ALTA-2L`

---

<!-- header: 'ALTA-1L: Brigatinib 1L' -->

## Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer

:::free

- phase III, Open-label
- Randomized
- 275 patients, 1:1
  - Advanced ALK-positive NSCLC patients
  - not previously received ALK inhibitors
- Brigatinib 180 mg QD
  - 7-day lead-in period at 90 mg
- Crizotinib 250 mg BID

:::split

| Outcome            | Brigatinib             | Crizotinib             |
| ------------------ | ---------------------- | ---------------------- |
| Estimated 12m PFS: | 67% (95% CI, 56 to 75) | 43% (95% CI, 32 to 53) |
| ORR                | 71% (95% CI, 62 to 78) | 60% (95% CI, 51 to 68) |
| Intracranial RR    | 78% (95% CI, 52 to 94) | 29% (95% CI, 11 to 52) |

- Trial: `ALTA-1L` NCT02737501

:::

> Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379(21):2027-2039. doi:10.1056/NEJMoa1810171

---

## Outcome

![Figure: width:1150px](https://i.imgur.com/xaGcPa7.png)

> Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379(21):2027-2039. doi:10.1056/NEJMoa1810171

---

## Survival without intracranial disease progression with brain metastasis at baseline

:::free

![Figure: height:450px](https://i.imgur.com/t6viSjx.png)
:::split
the confirmed rate of intracranial response among patients with measurable lesions was 78% (95% CI, 52 to 94) and 29% (95% CI, 11 to 52), respectively.
:::

> Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2018;379(21):2027-2039. doi:10.1056/NEJMoa1810171

---

<!-- header: 'ALTA-2' -->

## Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib

![Figure: width:1100px](https://i.imgur.com/egat1O1.png)

!!!note Median PFS 3.8 in this Phase 2 trial

> Ou SHI, Nishio M, Ahn MJ, et al. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of Thoracic Oncology. 2022;17(12):1404-1414. doi:10.1016/j.jtho.2022.08.018

---

#### In this study: ALK fusion and EML4 fusion detected at baseline in patients receiving previous alectinib or previous ceritinib

![Figure: width:1150px](https://i.imgur.com/IvoFPLi.png)

> Ou SHI, Nishio M, Ahn MJ, et al. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of Thoracic Oncology. 2022;17(12):1404-1414. doi:10.1016/j.jtho.2022.08.018

---

<!-- header: 'ALTA-3' -->

## Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial

![Figure: width:1150px](https://i.imgur.com/rhI1N5z.png)

---

### Brigatinib was not superior to alectinib for PFS in crizotinib-pretreated ALK+ NSCLC

![Figure: height:450px](https://i.imgur.com/D3S6Eqm.png)

> Yang JCH, Liu G, Lu S, et al. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. Journal of Thoracic Oncology. 2023;18(12):1743-1755. doi:10.1016/j.jtho.2023.08.010

---

<!-- header: 'ASCEND-5: ceritinib' -->

# <!--fit-->Ceritinib

## <!--fit-->Yet another 2nd generation ALKi

`ASCEND-5`

---

## First-line **ceri**tinib versus platinum-based chemotherapy

### ASCEND-4

- **Design:** Randomized, open-label, phase 3 trial involving 134 centers across 28 countries.
- **Number of patients:** 376 patients were randomly assigned to ceritinib (n=189) or chemotherapy (n=187).
- **Patients characteristics:** Untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC.
- **Agent:** Oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 weeks for four cycles followed by maintenance pemetrexed).
- **Treatment line:** First-line treatment.

> Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet. 2017;389(10072):917-929. doi:10.1016/S0140-6736(17)30123-X

---

## First-line **ceri**tinib versus platinum-based chemotherapy

### PFS 16.6 vs 8.1

![Figure: width:900px](https://i.imgur.com/y6DybBa.png)

the rapid development and approval of other next generation ALK inhibitor has **diluted** the importance of this finding.

> Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet. 2017;389(10072):917-929. doi:10.1016/S0140-6736(17)30123-X

---

## First-line **ceri**tinib versus platinum-based chemotherapy

:::free

### OS

![Figure: height:400px](https://i.imgur.com/USr5OsL.png)

:::split

![height:400px](https://i.imgur.com/bNpgA4G.png)

:::

> Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet. 2017;389(10072):917-929. doi:10.1016/S0140-6736(17)30123-X

---

<!-- header: 'CROWN: Lorlatinib' -->

![bg](https://i.imgur.com/cEFt6FK.jpg)

---

# <!--fit-->Lorlatinib

## <!--fit-->3rd generation ALKi

`CROWN 👑`

---

<!-- header: 'CROWN: Lorlatinib 1L' -->

## First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

:::free

- Phase 3, Randomized
- Multi-center, Open-label

- Number of patients: 296
  - Advanced ALK-positive NSCLC
  - Received no previous systemic treatment for metastatic disease

:::split

### Agent

- Lorlatinib, 100 mg once daily
- Crizotinib, 250mg BID

5. Treatment line: First-line treatment for advanced ALK-positive NSCLC

6. Trial Name or NCT Number: `CROWN 👑` ClinicalTrials.gov number, NCT03052608
   :::

> Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187

---

7. Comparison of two groups:

| Endpoint                                                                | Lorlatinib                  | Crizotinib             |
| ----------------------------------------------------------------------- | --------------------------- | ---------------------- |
| Progression-free survival at 12 months                                  | **78%** (95% CI, 70 to 84)  | 39% (95% CI, 30 to 48) |
| Hazard ratio for disease progression or death                           | 0.28 (95% CI, 0.19 to 0.41) | Not reported           |
| Objective response                                                      | 76% (95% CI, 68 to 83)      | 58% (95% CI, 49 to 66) |
| Intracranial response (among patients with measurable brain metastases) | 82% (95% CI, 57 to 96)      | 23% (95% CI, 5 to 54)  |
| Intracranial complete response                                          | 71%                         | Not reported           |

> Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187

---

![Figure: height:550px](https://i.imgur.com/te6p4q9.png)

> Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187

---

## Cumulative Incidence of CNS Progression as First Event

![Figure: height:450px](https://i.imgur.com/M1HqNZv.png)

> Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187

---

![Figure: height:550px](https://i.imgur.com/8A8x1xz.png)

> Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187

---

## Timeline in the development of the AEs of lorlatiib

:::free
![Figure: height:450px](https://i.imgur.com/C6KXBCA.png)
:::split
![Figure: height:450px](https://i.imgur.com/Z5vkkHb.png)
:::

> Ou SHI, Lee ATM, Nagasaka M. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Critical Reviews in Oncology/Hematology. 2023;187:104019. doi:10.1016/j.critrevonc.2023.104019
> Bauer TM, Felip E, Solomon BJ, et al. Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist. 2019;24(8):1103-1110. doi:10.1634/theoncologist.2018-0380

---

<!-- header: 'Compare Trials of ALKi' -->

<!-- ## Compare Trials of ALKi: PFS -->
<!---->
<!-- ![Figure: height:450px](https://i.imgur.com/sct97zN.png) -->
<!---->
<!-- --- -->
<!---->
<!-- ## Compare Trials of ALKi: Overall Survival -->
<!---->
<!-- ![Figure: height:450px](https://i.imgur.com/AHqyW84.png) -->
<!---->
<!-- --- -->

## Compare Trials of ALKi

![Figure: width:1150px](https://i.imgur.com/GRnGazB.png)

![Figure: width:1150px](https://i.imgur.com/kMckoG9.png)

---

## Schematic total PFS comparison

![Figure: height:480px](https://i.imgur.com/AFbYg7j.png)

> Ou SHI, Lee ATM, Nagasaka M. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Critical Reviews in Oncology/Hematology. 2023;187:104019. doi:10.1016/j.critrevonc.2023.104019

---

![bg fit](https://i.imgur.com/uCaA40P.png)

---

### ALK inhibitor versus chemotherapy, outcome: 1.1 Progression-free survival subgrouped by line of treatment

![Figure: height:550px](https://i.imgur.com/Ap7Lfbb.png)

---

### ALK inhibitor versus chemotherapy, outcome: 1.16 Overall survival subgrouped by line of treatment

![Figure: height:550px](https://i.imgur.com/0Pi6Yr9.png)

---

### Next-generation ALK inhibitor versus crizotinib, outcome: 2.1 Progressionfree survival subgrouped by type of ALK inhibitor

![Figure: height:500px](https://i.imgur.com/s0Buyuq.png)

---

### Next-generation ALK inhibitor versus crizotinib, outcome: 2.3 Overall adverse events subgrouped by type of ALK inhibitor

![bg right:70% height:600px](https://i.imgur.com/7Zg0mAB.png)

---

<!-- header: 'Kinase Resistance Problem' -->

# <!--fit-->Resistance <br>of ALKi

---

## Mechanisms of resistance of ALKi

:::free

![Figure: height:550px](https://i.imgur.com/RRcEHiI.png)

:::split

![height:200px](https://media.giphy.com/media/v1.Y2lkPTc5MGI3NjExaXhzaXl6ZTlhc280YnpzdjVhdWhvZDd0dXlrZWJpM2ZhbXd1Nmd1cSZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9Zw/j1iknYKFcHC20n9GXE/source.gif)

:::

> Dagogo-Jack I, Shaw AT. Crizotinib resistance: implications for therapeutic strategies. Ann Oncol. 2016;27(Suppl 3):iii42-iii50. doi:10.1093/annonc/mdw305

---

## Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer

![Figure: width:1150px](https://i.imgur.com/2Nf7iFk.png)

> Lin JJ, Zhu VW, Yoda S, et al. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. JCO. 2018;36(12):1199-1206. doi:10.1200/JCO.2017.76.2294

---

## PFS by EML4-ALK v1 versus v3 detected by cDNA (CROWN, ALEX, ALTAl-1L)

![Figure: height:450px](https://i.imgur.com/DsjXlhC.png)

> Ou SHI, Lee ATM, Nagasaka M. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Critical Reviews in Oncology/Hematology. 2023;187:104019. doi:10.1016/j.critrevonc.2023.104019

---

## Secondary Mutations within EML4-ALK

EML4-ALK cDNA clones prepared from sputum specimens obtained from our patient before crizotinib treatment and from pleural-effusion specimens obtained after relapse.

:::free

![Figure: height:350px](https://i.imgur.com/DSeDaE5.png)

:::split

![Figure: height:350px](https://i.imgur.com/iWeyKfI.png)

:::

> Choi YL, Soda M, Yamashita Y, et al. EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. New England Journal of Medicine. 2010;363(18):1734-1739. doi:10.1056/NEJMoa1007478
> Lovly CM, Pao W. Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance. Sci Transl Med. 2012;4(120). doi:10.1126/scitranslmed.3003728

---

## Characteristics of the pooled population of 450 ALK inhibitor resistant

![Figure: height:450px](https://i.imgur.com/YrQiut5.jpg)

> Koopman B, Groen HJM, Schuuring E, et al. Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. Clinical Lung Cancer. 2022;23(2):e104-e115. doi:10.1016/j.cllc.2021.06.011

---

## Clinical Benefit for ALK Resistance Mutations From Sequential ALK Inhibitors

![Figure: height:350px](https://i.imgur.com/tlNlrbC.png)

![bg right:50% height:580px](https://i.imgur.com/pieOODX.jpg)

> Koopman B, Groen HJM, Schuuring E, et al. Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. Clinical Lung Cancer. 2022;23(2):e104-e115. doi:10.1016/j.cllc.2021.06.011

---

![bg fit height:650px](https://i.imgur.com/uLszZCI.png)

> Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol. 2018;15(11):694-708. doi:10.1038/s41571-018-0081-4

---

<!-- header: '' -->

## Take Home Message

:::free

- `健保 2023-11-01`
  - Lorlatinib與alectinib、ceritinib、crizotinib、brigatinib用於ALK陽性之晚期非小細胞肺癌第一線治療時，僅得擇一使用
- Lorlatinib: Excellent CNS activity
- Lorlatinib AEs: hypercholesterolemia, hypertriglyceridemia, cognitive AEs, peripheral neuropathy, and edema
- Resistance of ALKi: **Variant 3 and G1202R**

:::split

![Figure: height:450px](https://i.imgur.com/1aYctXU.png)

:::split

![Figure: height:500px](https://i.imgur.com/79yvGyV.png)

:::

> Singh N, Jaiyesimi IA, Ismaila N, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1. JCO. 2023;41(15):e42-e50. doi:10.1200/JCO.23.00281

---

# Thank you for your time and attention

## <!--fit-->_Have a nice day_

![bg right:50% height:550px](https://media.tenor.com/Q-OWuADzjMQAAAAC/burp-leo.gif)

---

<!-- header: 'Adjuvant ALK Inhibitor' -->

## Addendum

# <!--fit-->Adjuvant <br>ALK Inhibitor

---

## ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer

![Figure: height:450px](https://i.imgur.com/TfSE66f.png)

---

#### ALINA: Randomized Phase III Trial of Adjuvant Alectinib vs Chemotherapy in Patients With Stage IB-IIIA ALK-Positive NSCLC

![Figure: height:550px](https://i.imgur.com/5e4cUuF.png)
